Patients lost to follow up (LTFU), expired during

the treatment (EX) and in whom HCV RNA by PCR was not checked (NoPCR) at any stage were excluded from the analysis. Results: Total seventy two patients were enrolled. Group A, B, C and D consisted of 13, 29, 11 and 19 patients, respectively. Seventeen patients were excluded from “per protocol treatment” analysis; 2 from group A (2- LTFU), 7 from group B (1 EX, 2-LTFU, 4-NoPCR), 3 from group C (3-NoPCR) and 5 from Group D (1-EX, 1-LTFU, 3-NoPCR). The final analysis was done in 55 patients. In group A, 11 out of 11 patients achieved ETR with a response rate (RR) of 100% while in group B, 11 out of 22 achieved ETR with a RR of 50%. In group C, 6 out of 8 achieved ETR with a RR of 75% while in group D, 3 out of 14 achieved ETR with a RR of 21.4%. For genotype 3 (Group A and B) URVR was significantly predictive of achieving

ETR (Corrected Yates chi square p value = 0.013). Similarly Neratinib chemical structure for genotype 1 (Group C and D) URVR was significantly predictive of achieving ETR (Corrected Yates Chi square p value =0.045). Conclusion: The URVR appears to be a good predictor of favorable treatment outcome for acute hepatitis C infection in patients on MH, especially in G3. Disclosures: The following people have nothing to disclose: Syed M. Hassan, Arzoo Saeed, Muhammad Osama Butt, Nasir Hassan Luck, Syed Mudassir Laeeq, Zaigham Abbas Background: Treatment of chronic hepatitis C (HCV) following liver transplantation has historically been challenging, with unsatisfactory Crizotinib datasheet sustained viral response (SVR) rates and poor interferon tolerability. Phase II data from COSMOS demonstrated high SVR rates in the non-transplant setting. Based on these observations, the Jewish Hospital Transplant Center (JHTC) has opted to treat

recurrent genotype 1 HCV in liver transplant recipients with simeprevir (150 mg daily) plus sofos-buvir (400 mg daily) (sim/sof) Methocarbamol with or without weight-based ribavirin (riba) for 12 weeks. The purpose of this study is to examine preliminary efficacy/safety. Methods: This IRB-ap-proved retrospective chart review examined the first 24 liver transplant recipients treated with sim/sof±riba at the JHTC. Baseline host/virus characteristics were analyzed as well as on-treatment viral kinetics, adverse events (AEs), and immu-nosuppressant dose adjustments. Results: 19 subjects were treatment experienced (17 nonresponders and 2 intolerant of interferon-based treatment regimens), while 5 were treatment naïve. 2 subjects had cirrhosis, but none had cholestatic HCV. 16 were genotype 1a (7 Q80K+ and 9 Q80K-) while 8 were genotype 1b. All genotype1a Q80K+ and 2 genotype 1a Q80K- subjects received sim/sof/riba while the others were treated with sim/sof. 19 subjects had initial viral loads >800,000 IU/mL. 19 subjects have reached at least treatment week 4. Of these, 17 had HCV RNA